Project Grant HT94252411095
Award Date
12/1/24
Completion Date
11/30/26
Dollars Obligated
$525K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
The Defense Health Agency (DHA) awarded Dana-Farber Cancer Institute, Inc. (DFCI) a $4,991,950 Project Grant under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, awarded on November 1, 2024, will fund an investigation of a multi-cancer early detection test in a high-risk military population. The project aims to advance medical research and improve healthcare for military service members and the broader public. DFCI, a prestigious non-profit cancer...
The Dana-Farber Cancer Institute, Inc. (DFCI) was awarded a $2,136,000.00 Project Grant from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, with a performance period from May 1, 2025 to April 30, 2028, will support research focused on "Reversibility and Therapeutic Targeting of Treatment-Emergent Neuroendocrine Prostate Cancer." DFCI, a prestigious nonprofit cancer research center in Boston, MA, will...
The Defense Health Agency has awarded a $4,954,747 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to conduct research under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "Novel Immunologic Discovery Platforms to Prevent Metastasis and Recurrence in Breast Cancer," will fund a four-year research project focused on developing new immunology-based approaches to prevent the spread and return of breast cancer. As a...
The Defense Health Agency has awarded a $1,483,340 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as DFCI) in Boston, MA. The grant, with a performance period from June 1, 2024 to May 31, 2028, will fund research to harness extracellular domain (ECD) cleavage of anaplastic lymphoma kinase (ALK) for immunotherapy against neuroblastoma. As a non-profit hospital and cancer research center, DFCI will...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $889,995.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (dba Dfci), a non-profit hospital and cancer research center in Boston, MA. The grant, effective June 1, 2024 through May 31, 2027, supports research to "dissect the interplay of molecular and spatial architectures with clinical states in prostate cancer." This federal funding will enable Dana-Farber to conduct...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $1,229,700.00 to the Dana-Farber Cancer Institute, Inc. (DFCI) to support research on the molecular associations of response to neoadjuvant antiandrogen therapies in high-risk localized prostate cancer. The award, which runs from August 15, 2024 to August 14, 2028, will enable DFCI, a leading cancer research institution, to conduct advanced biomedical...
The Defense Health Agency has awarded a $657,263 project grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (d.b.a. DFCI) in Boston, MA. The award, effective September 1, 2024 through August 31, 2027, will support DATA-DRIVEN BIOMARKER-INFORMED DECISION ANALYTICS IN MELANOMA: IMPROVING EFFICACY AND REDUCING TOXICITY OF IMMUNE CHECKPOINT BLOCKADE. Through this grant, DFCI will conduct research to develop data-driven...
The U.S. Defense Health Agency has awarded a $712,000 Project Grant through the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) in Boston, MA. The 2-year grant, with a period of performance from July 1, 2024 to June 30, 2026, will support a longitudinal study to identify mechanisms of treatment resistance in rhabdomyosarcoma through circulating tumor DNA analysis. As a not-for-profit hospital and cancer research...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
Under the $534,000.00 Project Grant awarded by the Defense Health Agency through the Military Medical Research and Development program (CFDA 12.420), the Dana-Farber Cancer Institute, Inc. (doing business as DFCI) will conduct research to define the role of the androgen receptor in BRCA1/2-deficient prostate cancer. This translational research aims to improve understanding of disease dependencies and develop new treatment approaches for this challenging cancer type. DFCI, a non-profit hospital...